New combo therapy aims to slow aggressive gut tumors
NCT ID NCT07185672
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This phase 3 trial tests whether adding chemotherapy (capecitabine and temozolomide) to standard peptide receptor radionuclide therapy (PRRT) helps people with a specific type of advanced neuroendocrine tumor live longer without the disease getting worse. The study enrolls 162 adults whose tumors show high activity on a PET scan. The goal is to find a better way to control these aggressive tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASIA'S (NENS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
RECRUITINGNavi Mumbai, Maharashtra, 410210, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tata Memorial Hospital, Mumbai, India
RECRUITINGMumbai, Maharashtra, 400012, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.